Followers | 4216 |
Posts | 13632 |
Boards Moderated | 6 |
Alias Born | 12/14/2012 |
![](https://investorshub.advfn.com/uicon/373082.png?cb=1467743948)
Friday, January 22, 2021 12:33:03 AM
1. Their soon to be approved industry-leading hemostatic gauze that provides the means to quickly control bleeding from open wounds with a cost effective, high efficiency product;
2. The competency and dedication of its management and medical team in the conduct of BOTH their financial affairs AND their scientific research and development of marketable products relevant to improvement of today's surgical techniques;
3. The company's disciplined and methodical approach to their application with the Food & Drug Administration to gain approval to market HemoStyp as a hemostat in the human surgical setting; currently it is approved for use in medical applications for superficial bleeding and certain dental procedures. This is a REAL product with REAL market possibilities once FDA approval has been granted for the surgical procedures.
4. The share structure with a relatively very low float (99,945,675 shares) for a small cap OTC stock further indicates a very disciplined corporate board that does not issue stock as a means to raise revenue in the administration of the company. Such actions (issuance of stock) always served to dilute shareholders' value by lowering the stock price usually for the financial benefit of the corporate board.
UEEC--Have you researched the company and their reports?
Did you research the standard of care presently from Johnson and Johnson?
UEEC'S products are statistically MUCH more effective than the aforementioned and can be utilized in humans and animals. Are you aware of this data?
All of the insiders temporarily waived much of their prior salaries to advance the company money while they progressed through the FDA approval process, are you aware of this?
How about the de minimus share structure relative to their market capitalization now, versus post FDA approval?
I could go on and on and on.
DD is the foundation by which we find equities that are undervalued and unknown and profit off of both.
Recent UEEC News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:16:02 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 10:05:42 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 09:10:10 PM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM